5-hydroxydecanoate has been researched along with gw9662 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nagashima, K; Narentuoya, B; Nishigaki, K; Sumi, S; Takemura, G; Ushikoshi, H; Yamaki, T; Yasuda, S | 1 |
1 other study(ies) available for 5-hydroxydecanoate and gw9662
| Article | Year |
|---|---|
Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Topics: Androstadienes; Anilides; Animals; Blood Glucose; Blotting, Western; Decanoic Acids; Disease Models, Animal; Enzyme Activation; Hemodynamics; Hydroxy Acids; Hypoglycemic Agents; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Pioglitazone; Potassium Channel Blockers; Potassium Channels; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rabbits; Thiazolidinediones; Time Factors; Ventricular Function, Left; Wortmannin | 2009 |